Company: DHR
Filing Date: 2025-04-22
Form Type: 10-Q
Source: 0000313616-25-000088
Chunk: 33

Company: DANAHER CORP /DE/
Filing Date: 2025-04-22
Form: 10-Q
Item: Item 1
Chunk 33
---
 to a facility in the Biotechnology segment - 25 basis points

23

First quarter 2025 vs. first quarter 2024 operating profit margin comparisons were favorably impacted by:

•First quarter 2024 acquisition-related fair value adjustment to inventory - 40 basis points

Business Segments

Sales by business segment for each of the periods indicated were as follows ($ in millions):

 Three-Month Period Ended March 28, 2025March 29, 2024Biotechnology$1,612 $1,524 Life Sciences1,680 1,745 Diagnostics2,449 2,527 Total$5,741 $5,796 

For information regarding the Company’s sales by geographical region, refer to Note 4 to the accompanying Consolidated Condensed Financial Statements.

BIOTECHNOLOGY

The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a broad range of equipment, consumables and services that are primarily used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines.  The Company’s solutions support a broad range of biotherapeutics including monoclonal antibodies, recombinant proteins, replacement therapies such as insulin and vaccines, as well as novel cell, gene, mRNA and other nucleic acid therapies.

Biotechnology Selected Financial Data 

 Three-Month Period Ended($ in millions)March 28, 2025March 29, 2024Sales$1,612 $1,524 Operating profit441 325 Depreciation34 42 Amortization of intangible assets213 218 Operating profit as a % of sales27.4 %21.3 %Depreciation as a % of sales2.1 %2.8 %Amortization as a % of sales13.2 %14.3 %

Sales Growth and Core Sales Growth% Change Three-Month Period Ended March 28, 2025 vs. Comparable 2024 PeriodTotal sales growth (GAAP)6.0 %Impact of:Currency exchange rates 1.0 %Core sales growth (non-GAAP)7.0 %

Price increases in the segment contributed 1.0% to sales growth on a year-over-year basis during the three-month period ended March 28, 2025 and are reflected as a component of core sales above.

Total segment sales increased 6.0% during the three-month period